Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 207
Selected: 0
NCT IDTitle
NCT03261947A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
NCT01193244Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
NCT01085643Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
NCT00830869A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
NCT03477903TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)
NCT01874665A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
NCT01588470Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
NCT01167543Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
NCT01425008Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
NCT00807495Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
NCT03535740A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
NCT02045095A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors
NCT00161707Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency
NCT01023620HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
NCT03330106A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
NCT01830816Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
NCT00242177Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability
NCT01096290Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications
NCT03312894Efficacy and Safety of TAK-653 in Treatment-Resistant Depression
NCT01162863Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
NCT01666314Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
NCT03870555A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants
NCT02443922Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM
NCT00642694Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon
NCT01328392Evaluating Treatment Response in Laryngo-Pharyngeal Reflux
NCT02214147Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
NCT01898078Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
NCT00671515Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
NCT01592136Expanded Access Program of Ponatinib
NCT02094573A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
NCT05479721LITMUS Imaging Study
NCT03748953Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
NCT00391755A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches
NCT02412722A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
NCT00722137Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT00982202Pioglitazone in Alzheimer Disease
NCT01235741A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
NCT00500903A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
NCT00753623Clinical Management of Neuropathic Pain With Ramelteon
NCT00502320Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder
NCT03047369The Myelin Disorders Biorepository Project
NCT00932698Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
NCT03482453A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants
NCT00963820Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
NCT01449370Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
NCT02259010A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
NCT03439280A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
NCT00904046Pathophysiology of Uric Acid Nephrolithiasis
NCT04563520SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
NCT03500224A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants